Richard Kim

Children's Health & Therapeutics Dr. Richard Kim


Scientist, Division of Children’s Health and Therapeutics, Children’s Health Research Institute
Scientist, Lawson Health Research Institute
Chair & Professor, Division of Clinical Pharmacology, Department of Medicine, Schulich School of Medicine & Dentistry, Western University
Director, Centre for Clinical Investigation & Therapeutics, Western University
Associate Chair for Research, Department of Medicine, Schulich School of Medicine & Dentistry, Western University
Professor, Departments of Physiology & Pharmacology and Oncology, Schulich School of Medicine & Dentistry, Western University

How my research helps children

My research is focused on better understanding the molecular determinants of interindividual variation in drug response. Specifically, the focus has been that of pathways governing drug metabolism and transport in organs such as the intestine, liver, and kidney. Our group has identified a number of genetic polymorphisms in the genes which affect how drugs are cleared by the body, and have used such information to conduct research in the area of Personalized Medicine. Our research in Personalized Medicine will have an important impact to the safe and effective use of drugs for children.


Current Research Activities

We are involved in translational research in the area of anticoagulant and lipid lowering drugs. We also have a range of research being conducted in relation to anticancer drugs.

Research Team

We have a large multidisciplinary team consisting of physicians, PhD scientists, pharmacists, residents, nurses, graduate students, post-doctoral fellows, research associates and coordinators. A recent photo of our group is shown below.

Future Research Plans

We will continue our focus on clinical research, especially in the area of Personalized Medicine. Of relevance to CHRI, we are in collaboration with pediatricians in the Department of Pediatrics such as Dr. Kevin Bax and Dr. Ralf Rauch in relation to drugs used in children for GI disorders and anticoagulation.

Awards & Grants

Awards & Grants

2010-2015    Cancer Care Ontario Research Chair (Level 1)

2009-2011     President, Canadian Society of Pharmacology and Therapeutics

2007-2009    Chair, American Society for Pharmacology and Experimental Therapeutics (ASPET) Division of Clinical Pharmacology, Pharmacogenomics, & Translational Medicine

2008    Lawson Innovation Prize, Lawson Health Research Institute, London Ontario.   

2006    Elected Member, American Society for Clinical Investigations (ASCI)

2005    Pioneering Work in Drug Transport Award, Southern California Drug Metabolism Discussion Group

2005     Elected Fellow, American Association of Pharmaceutical Scientists (AAPS)2008    Lawson Innovation Prize, Lawson Health Research Institute, London Ontario.   

Recent Publications


Human multidrug and toxin extrusion 1 (MATE1/SLC47A1) transporter: Functional characterization, interaction with OCT2, and single nucleotide polymorphisms
Meyer Zu Schwabedissen HE, Verstuyft C, Kroemer HK, Becquemont L, Kim RB
Am J Physiol Renal Physiol. 2010; 298:F997-F1005

Human skeletal muscle drug transporters determine local exposure and toxicity of statins
Knauer MJ, Urquhart BL, Meyer zu Schawabedissen HE, Schwarz UI, Lemke CJ, Leake BL, Kim RB, Tirona RG
Circ Res. 2010; 106:297-306

Polymorphic variants in the human bile salt export pump (BSEP; ABCB11): functional characterization and interindividual variability
Ho RH, Leake BF, Kilkenny DM, Meyer zu Schwabedissen HE, Glaeser H, Kroetz DL, Kim RB
Pharmacogenet Genomics. 2010; 20:45-57

Modulation of intestinal expression and function by drugs
Urquhart BL, Gregor JC, Chande N, Knauer MJ, Tirona RG, Kim RB, The human proton-coupled folate transporter (PCFT)
Am J Physiol Gastroentest Liver Physiol. 2010; 298:G248-254

Identification, Expression, and Functional Characterization of Full-Length and Splice Variants of Murine Organic Anion Transporting Polypeptide 1b2
Meyer zu Schwabedissen HE, Ware JA, Tirona RG, Kim RB
Mol Pharm. 2009; 6:1790-1797

The organic cation transporter, OCTN1, expressed in human heart, potentiates ion channel antagonism
McBride BF, Yang T, Liu K, Urban TJ, Giacomini KM, Kim RB, Roden DM
J Cardiovasc Pharmacol. 2009; 54:63-71

Overexpression of OATP1B3 confers apoptotic resistance in colon cancer
Lee W, Lockhart AC, Merchant N, Glaeser H, Harris EI, Washington K, Zaika A, Kim RB, El-Rifai W
Cancer Res. 2008; 68:10315-10323

Interplay between the nuclear receptor PXR and the uptake transporter OATP1A2 selectively enhances estrogen effects in breast cancer
Meyer zu Schwabedissen H, Tirona RG, Yip CY, Ho RH, Kim RB
Cancer Res. 2008; 68:4983-4989

Transporter mediated protection against thiopurine-induced hematopoietic toxicity
Krishnamurthy P, Schwab M, Takena K, Nachagari D, Morgan J, Leslie M, Du W, Boyd K, Cheok M, Nakauchi H, Marzolini C, Kim RB, Poonkuzhali B, Schuetz E, Evans W, Relling M, Schuetz JD
Cancer Res. 2008; 68:4983-4989

Targeted disruption of murine organic anion-transporting polypeptide 1b2 (oatp1b2) significantly alters disposition of prototypical drug substrates pravastatin and rifampin
Zaher H, Meyer zu Schwabedissen H, Tirona RG, Cox M, Obert L, Agrawal N, Palandra J, Stock JL, Kim RB, Ware JA
Mol Pharmacol. 2008; 74:320-329

Additional publications



Phone: (519) 663-3553
Fax: (519) 663-3232
E-mail: richard [dot] kim [at] lhsc [dot] on [dot] ca

(Please note: CHRI is not responsible for the content of any external sites - links will open in new window)